ImmuneRegen Confirms Homspera's Anti-Influenza Effect on H1N1 After Oral Administration
Preliminary evidence has shown that ImmuneRegen BioSciences' selective Neurokinin 1-receptor agonist Homspera is active on oral administration and provides therapeutic effects against the current pandemic H1N1 virus infection.
Preliminary evidence has shown that ImmuneRegen BioSciences' (Scottsdale, AZ) selective Neurokinin 1-receptor agonist Homspera is active on oral administration and provides therapeutic effects against the current pandemic H1N1 virus infection.
Preliminary analysis of ongoing bioavailability studies in rats had revealed the oral administration of Homspera resulted in measurable amounts of the drug in lung tissue. Systemic absorption and accumulation in lungs was found after both oral and intra-duodenal administration in studies performed by a contract research organization with analytical work performed at MDxBioanalytical, Inc. (Tucson, AZ).
Based on these findings, the company commissioned H1N1 virus studies to be performed. Using the accepted ferret model of H1N1 influenza virus infection, animals were treated orally (initially) with Homspera starting 24 hours after infection. Although data collection and analysis is ongoing, preliminary evaluation of temperatures of infected ferrets reveals that orally administered Homspera lessened the impact of influenza infection, resulting in shortened duration and more rapid resolution of the hyperthermia associated with infection.
Immune markers of infection remain to be assessed, but this pilot study reveals that the ability of Homspera to attenuate symptoms of influenza virus infection, which have previously been reported in cotton rats infected with H3N2 influenza and in ferrets infected with H5N1 influenza, also extends to the current pandemic H1N1 strain.
These preliminary results support the hypothesized mechanism of Homspera’s immune system activation and expand the therapeutic range over which activity of the compound has been shown in accepted animal models.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
